News

BMS, Sanofi-Aventis Settle Over Generic Plavix

Spotlight on Products from Interphex

Actavis Makes $1.6 Billion Takevoer Bid for Pliva

Implementing a PAT Strategy

US Government Increase Orders for Flu Treatment from Roche, GSK

RFID and the Future of Pharmaceutical Supply Chains

Gottlieb Challenges Manufacturers to Make Processes More Efficient

Interphex FasterCures Keynote Speaker Stresses Communication and Collaboration

Bayer Bids for Schering AG in Friendly Merger Offer

Fundamentals Stay Strong for Pharma Contract Services Industry

FDA's Risk-based Model Leads to Strategies for Optimizing Site Risk Potential

Merck KGaA Launches Bid For Schering AG

Bush Administration Nominates von Eschenbach to head FDA

Chiron Withdraws Measles Vaccine

Roche Expands "Tamiflu" Production

Novasep Divests Swiss Fine Chemicals Producer Rohner AG

Watson To Acquire Andrx for $1.9 Billion

GSK Loses Bid to Block Generic "Flonase"

Development Begins on Mutated H5N1 Virus Vaccine

Proposed Legislation to Help Fight Counterfeit Drugs

Schering-Plough Reorganizes Management in Europe, Latin America and Asia-Pacific

Novavax, Bharat Biotech Team for Pandemic Influenza Vaccine Development

Eisai Plans $105 Million Pharma Production and Formulation R&D Facility

BMS Plans to Build $660 Million Bulk Biologics Manufacturing Facility

Flu vaccines. Dow veterinary vaccine made in plants. $1.95 billion FDA budget focuses on high-profile programs. Non-injectable insulins win approval. FDA releases guides to dissolution testing, quality overall summary, and new drug-label formats.

A modified modular high-pressure system can form nanosuspensions of model compounds by individually controlling cavitation, impact, and shear forces.

P&G Pharmaceuticals Plans Job Cuts

Chiron and Novartis Advance Programs for Pandemic Flu

Chiron To Sell Betaseron Assets to Schering

Letter to the Editor: Glen Jon Smith